ACT Capital Management LLC Purchases New Position in Abivax SA Sponsored ADR $ABVX

ACT Capital Management LLC purchased a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the fourth quarter, Holdings Channel reports. The firm purchased 63,900 shares of the company’s stock, valued at approximately $8,617,000. Abivax accounts for 7.0% of ACT Capital Management LLC’s holdings, making the stock its 4th largest position.

Other hedge funds also recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its holdings in Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after buying an additional 369 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Abivax by 661.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after buying an additional 344 shares during the period. T. Rowe Price Investment Management Inc. purchased a new stake in Abivax during the fourth quarter worth $61,000. WPG Advisers LLC lifted its holdings in Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after buying an additional 253 shares during the period. Finally, Union Bancaire Privee UBP SA purchased a new stake in Abivax during the fourth quarter worth $67,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Trading Up 2.7%

Shares of ABVX stock opened at $100.15 on Thursday. The business’s fifty day simple moving average is $114.81 and its 200-day simple moving average is $118.49. The company has a market cap of $7.99 billion, a PE ratio of -19.22 and a beta of 0.69. Abivax SA Sponsored ADR has a 12-month low of $5.69 and a 12-month high of $148.83.

Abivax (NASDAQ:ABVX) last released its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. On average, equities analysts forecast that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on ABVX shares. Citigroup restated an “outperform” rating on shares of Abivax in a report on Tuesday, June 2nd. Oddo Bhf restated an “outperform” rating on shares of Abivax in a report on Thursday, April 9th. BTIG Research restated a “buy” rating and set a $150.00 target price on shares of Abivax in a report on Tuesday. Barclays upped their price target on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Finally, Wedbush raised Abivax from an “underperform” rating to a “neutral” rating and reduced their price target for the stock from $110.00 to $90.00 in a research report on Tuesday, June 2nd. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Abivax has an average rating of “Moderate Buy” and a consensus price target of $130.08.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.